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The so-called epigenetic drugs are a relatively new class
of drugs acting on chromatin enzymatic and non-purely
enzymatic complexes, for which interest has grown
exponentially in the last decade. Indeed, huge research
efforts have been initiated within academia to address
chemical as well as biological aspects of epigenetic drugs
and their targets. This growing interest is paralleled by
strong investments in exploring new epigenetic drugs by
(big) pharma. In addition, the interest of clinicians to
explore epigenetic mechanisms and epi-marks as
therapeutic tools for a patient’s stratification and therapy
is currently reaching far beyond the initial field of
oncology.
Despite the growing awareness of the role of epi-
genetic dysregulation as cause-and/or-effect in disease
and the exploding number of modulating compounds,
many aspects remain unaddressed and require further
improvement.
Given this urgent need, we present in this series an
overview of state-of-the-art knowledge of drug design
for old and new epi-targets, their mechanisms of actions,
and the increasing spectrum of clinical applications. In
addition, we introduce an European Cooperation in
Science and Technology (COST) platform to address open
questions, directions, and potential emerging concerns
(see Table 1).
One of the concerns is the relatively wide effect of
epigenetic modulating mechanisms: next to the
intended upregulation of, for example, tumor suppres-
sor genes in cancer, metastasis genes might also
become upregulated as an unwanted side effect. This
realization results in seemingly contradictory ap-
proaches of exploring synergisms of inhibiting writers
(DNA methyltransferase (DNMTs)), while increasing
the substrate of these enzymes (SAM) to stimulate
activity [1]. Similarly, efforts are being undertaken not
only to inhibit HDAC activity as an anticancer
approach but to focus on identifying HAT inhibitors as
well. The underlying rationale of such counterintuitively
contradictory approaches is based on differential gene
expression dysregulation associated within any given
diseases: some genes are aberrantly overexpressed
while others are repressed.
The success of such opposing strategies can also be ex-
plained by our current lack of knowledge on the mechan-
ism of action of the enzymes: largely unknown parameters
are involved including complex formation, microenviron-
ment conditions [2], and context-specific control. Upcom-
ing technologies such as multi-omics single-cell analyses [3]
and epigenetic editing [4, 5] may allow localized detections
and gene-targeted changes, which might turn essential in
fine-tuning such parameters. Eventually such insights may
also allow a better rational design of drugs (and combin-
ation of), further exploiting the promise of epigenetic drugs
and potentially the revitalization of the so-called old drugs.
In addition to the current lack of knowledge on mecha-
nisms of action on chromatin modulation and dedicated
epidrugs, we have only slowly started to unravel the wide
spectrum of substrates of the supposed epigenetic en-
zymes. Epidrugs are designed to inhibit (or activate)
histone-modifying enzymes or DNA methyltransferases,
or to interfere with readers of the resulting chromatin
modifications. However, it is more and more accepted that
these chromatin modifiers (and the dedicated epidrugs)
affect various other classes of substrates, including pro-
teins in signaling pathways and cellular architecture. If, for
oncology applications, this might be an additional advan-
tage as cancer cell death is the intended ultimate out-
come, for other clinical applications, greater insight
into the long-term effects is warranted.
Learning from the present knowledge, valproic acid has
been prescribed for epilepsia patients for several decades
now, without reporting serious side effects [6], and even
some cancer-preventive effects were documented [7].
Comparably, 5aza, first tested on Myeloid Dysplastic Syn-
drome patients, did not display important side effects even
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when a long-term vision was applied, suggesting that
worries might rely more in acquired resistances than
in intrinsic toxicity.
These two drugs are mere examples of the principal
two classes of epidrugs to obtain FDA approval: DNA
methyltransferase inhibitors for treatment of MDS
(azacitidine, in 2004) and histone deacetyltransferase
inhibitors for T cell lymphoma (Vorinostat, in 2006).
Currently, five histone deacetylase inhibitors and two
DNA methyltransferase inhibitors are FDA approved,
and developments in their respective areas are discussed
in reviews #3, #4, and #5.
As a results of the growing awareness of the wide
spectrum of epigenetic mutations and deregulations
underlying cancer (and many other diseases), more and
more insights are obtained on the (dys)function of other
chromatin modifying enzymes, and many of these are
currently explored as therapeutic targets as well as
potential bio-markers (series review #s 6–11).
Although all new therapeutic targets face challenges
when tested in biological systems, for epigenetic en-
zymes this is even more complex: How to interpret cell
toxicity assay data for inhibitors of histone-modifying
enzymes which actually do affect many more pathways
in the cellular compartment? What degree of differential
effects can be attributed given that the effect of the
enzymes is frequently dependent on the complex the
enzyme functions in?
The final outcome of a novel drug may not rely on the
catalytic action or at least not only. In addition, 3D
chromatin structure and the interplay of stable and
transitory interactions (and potential priorities dictated by
the presence or the absence of some deposited marks)
should be also taken into account suggesting a further
level of complexity for chromatin complexes (and
epi-enzymes). Finally, the functional effect of epigenetic
modifications with respect to gene expression is highly
context-dependent.
Altogether, inhibitors (and the few activators known so
far) of epigenetic enzymes should be tested in carefully
chosen biological systems, incorporating adequate readout
assays and solid controls. Series reviews #s 12–16 set out
to address such biological questions and provide an over-
view of the status of several epigenetic drugs in oncology,
metabolic dysregulation, and neurodegeneration. Finally,
the promises of epigenetic drugs in regenerative medicine
are also discussed (review # 17).
The last part of the series (series review #s 18–20)
addresses important technological advances to be taken
into consideration for the development of potent epigen-
etic drugs. Overall, we feel that the current “epi-drug
era” opens novel avenues for various diseases beyond
cancer, but several aspects should be taken into account
to fulfill the promise of reversing epigenetic mutations
by genome-wide acting epigenetic enzyme inhibitors.
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